Beyond taxanes: The next generation of microtubule-targeting agents

Breast Cancer Research and Treatment

Volumn 133, Issue 3, 2012, Pages 821-830

  Cortes, Javier ^a   Vidal, Maria ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Epothilones; Eribulin; Ixabepilone; Microtubule targeting agents; Taxanes

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERIBULIN; GEMCITABINE; INDIBULIN; ISPINESIB; IXABEPILONE; LAPATINIB; MICROTUBULE TARGETING AGENT; NAVELBINE; PACLITAXEL; SAGOPILONE; TAXANE DERIVATIVE; TESETAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG; VINFLUNINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ASTHENIA; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE ARREST; CONSTIPATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; LEUKOPENIA; MEDLINE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SOLID TUMOR; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPOTHILONES; FEMALE; HUMANS; NEOPLASM METASTASIS; TAXOIDS; TUBULIN MODULATORS;

EID: 84863720339     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1875-6     Document Type: Review

References (66)

1. Telli ML, Carlson RW (2009) First-line chemotherapy for met-astatic breast cancer. Clin Breast Cancer 9(suppl 2):S66-S72
2. Surveillance epidemiology and end results. SEER stat fact sheets: breast. http://seer.cancer.gov/statfacts/html/breast.html#survival. Accessed 4 Nov 2010
3. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Casti-glione M (2010) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5):v15-v19
4. Yardley DA (2008) Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Clin Breast Cancer 8(6):487-492
5. Moreno-Aspitia A, Perez EA (2009) Treatment options for breast cancer resistant to anthracyclines and taxane. Mayo Clin Proc 84(6):533-545
6. TM. Breast cancer. V.3.2010. http://www. nccn.org. Accessed 4 Nov 2010
7. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676
8. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239-3247
9. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bev-acizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252-1260
10. Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101(23):1642-1649
11. McGrogan BT, Gilmartin B, Carney DN, McCann A (2008) Taxanes, microtubules and chemoresistant breast cancer. Bio-chim Biophys Acta 1785(2):96-132
12. Fojo T, Menefee M (2007) Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 18(suppl 5):v3-v8
13. Chien AJ, Moasser MM (2008) Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Sem Oncol 35(suppl 2):S1-S14
14. Katsetos CD, Legido A, Perentes E, Mork SJ (2003) Class III b-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol 18(12):851-866
15. Kamath K, Wilson L, Cabral F, Jordan MA (2005) bIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280(13): 12902-12907
16. Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M (2006) The bI/bIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J 273(14):3301-3310
17. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A et al (2005) Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16(suppl 4):iv14-iv19
18. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A et al (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of b-tubulins. Int J Cancer 120(10):2078-2085
19. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H (1996) Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 49(6): 560-563
20. Rivera E, Lee J, Davies A (2008) Clinical development of ix-abepilone and other epothilones in patients with advanced solid tumors. Oncologist 13(12):1207-1223
21. Vahdat L (2008) Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 13(3):214-221
22. Jordan M, Miller H, Ni L, Castenada S, Inigo I, Kan D et al. (2006) The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression, and is sensitive to ixabepilone. Proc Am Assoc Cancer Res 47:abstract LB-280
23. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW et al (2009) Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 63(2):201-212
24. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reven-tos-Suarez C et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7(5):1429-1437
25. Lee FY, Camuso A, Castaneda S, Flefleh C, Ingio I, Kan D et al. (2006) Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 24(sup-pl):abstract 12017
26. Lee FYF, Covello KL, Castaneda S, Hawken DR, Kan D, Lewin A et al (2008) Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 14(24):8123-8131
27. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane and capecitabine. J Clin Oncol 25(23):3407-3414
28. Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25(23):3399-3406
29. Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25(23):3415-3420
30. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX et al (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23(12):2726-2734
31. Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U et al (2007) Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25(23):3421-3427
32. Thomas E, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33):5210-5217
33. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF et al (2010) Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 122(2):409-418
34. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C et al (2010) Randomized phase III trial of ixabepilone plus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28(20):3256-3263
35. Conte P, Roche H, Perez E, Sparano J, Xu B, Jassem J et al. (2009) Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies. Cancer Res 69(suppl):abstract 6114
36. Perez EA, Patel T, Moreno-Aspitia A (2010) Efficacy of ixab-epilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 121(2):261-271
37. Roche H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J et al (2011) Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat 125(3):755-765
38. Rugo HS, Roche H, Thomas E, Blackwell K, Chung HC, Lerzo G et al. (2009) Ixabepilone plus capecitabine vs capecitabine in patients with triple-negative tumors: a pooled analysis of patients from two large phase III clinical studies. Cancer Res 69(sup-pl):abstract 3057
39. Yardley DA (2010) Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer 10(1):64-71
40. Moulder S, Li H, Gradishar WJ, Gradishar WJ, Perez EA, Sparano JA et al (2010) A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an eastern cooperative oncology group trial. Breast Cancer Res Treat 119(3):663-667
41. Chuang E, Wiener N, Christos P, Kessler R, Cobham M, Donovan D et al (2010) Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Ann Oncol 21(10):2075-2080
42. Roche H, Zambetti M, Dalenc F, Govi S, Gladieff L, Mudenda B et al. (2008) Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer. J Clin Oncol 26(suppl):abstract 1058
43. Rugo HS, Campone M, Amadori D, Wardley AM, Aldrighetti D, Conte PF et al. (2010) Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J Clin Oncol 28(suppl):abstract 1040
44. Cheng KL, Bradley T, Budman DR (2008) Novel microtubule-targeting agents-the epothilones. Biologics 2(4):789-811
45. Conlin AK, D'Andrea G, Hudis CA, Robson ME, Drullinsky P, Theodoulou M et al. (2008) Phase II trial of patupilone in patients with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT). J Clin Oncol 26(suppl):abstract 1086
46. Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M et al (2010) Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Res Treat 123(3):837-842
47. Cigler T, Vahdat LT (2010) Eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 11(9):1587-1593
48. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D et al (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halchondrin B macrocyclic ketone analog E7389. Cancer Res 64(16):5760-5766
49. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E et al (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27(18):2954-2961
50. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H et al (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28(25):3922-3928
51. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat L, Pe-trakova K et al (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914-923
52. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA (2010) Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or meta-static breast cancer. Clin Breast Cancer 10(2):160-163
53. Zhang Y, Xu W (2008) Progress on kinesin spindle inhibitors as anti-cancer agents. Anticancer Agents Med Chem 8(6):698-704
54. Purcell JW, Davis J, Reddy M, Martin S, Samayoa K, Vo H et al (2010) Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin Cancer Res 16(2):566-576
55. Miller, K, Ng C, Ang P, Brufsky AM, Lee SC, Dees EC et al. (2005) Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer. Breast Cancer Res Treat 94(suppl):abstract 1089
56. Burris HA III, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L et al (2011) A phase I study of ispinesib, a kinesin spindle inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 29(3):467-472
57. Blagden SP, Molife LR, Seebaran A, Payne M, Reid AH, Pro-theroe AS et al (2008) A phase I trial of ispinesib, a kinesin spindle inhibitor, with docetaxel in patients with advanced tumors. Br J Cancer 98(5):894-899
58. Jones SF, Plummer ER, Burris HA, Razak AR, Meluch AA, Bowen CJ et al. (2006) Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 24(suppl):abstract 2027
59. Rodon J, Till E, Patnaik A, Takimoto C, Beeram M, Williams D et al. (2006) Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors. Eur J Cancer Supp 4(12):abstract 640
60. Bennouna J, Delord J-P, Campone M, Nguyen L (2008) Vinflu-nine: a new microtubule inhibitor agent. Clin Cancer Res 14(6):1625-1632
61. Campone M, Cortes-Funes H, Vorobiof D, Martin M, Slabber CF, Ciruelos E et al (2006) Vinflunine: a new active drug for second-line treatment of advanced breast cancer, Results of a phase II and pharmacokinetic study inpatients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 95(9):1161-1166
62. Fumoleau P, Cortes-Funes H, Taleb AB, Chan S, Campone M, Pouget JC et al (2009) Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol 32(4):375-380
63. Yardley DA, McCleod M, Schreiber F, Yardley DA, McCleod M, Schreiber F et al (2010) A phase II trial of vinflunine as mono-therapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest 28(9):925-931
64. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A (2003) DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94(5):459-466
65. Wiencke A, Bacher G (2009) Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin. Cancer Res 69(1):171-177
66. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A et al (2001) D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 61(1):392-399